Tracey Mullen

CEO at Abveris

Tracey Mullen, MBA is a chemical-biological engineer from MIT with over a decade of experience in antibody discovery. In her most recent scientific role, she served on the antibody discovery team at Biogen where she helped implement the technology transfer of the Adimab platform for antibody engineering. Tracey joined Abveris as the Director of Antibody Discovery Operations, where she managed project design and development for therapeutic campaigns. After being promoted to Chief Operating Officer, she split her time between managing operations and co-leading the implementation of the Beacon single B cell screening platform for antibody discovery. Tracey is now CEO of Abveris and focuses on strategic organizational improvement through continued technical innovation.